Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.

Autor: Kolonen A; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Sinisalo M; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Huhtala H; Faculty of Social Sciences, Tampere University, Tampere, Finland., Rimpiläinen J; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Rintala H; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Sankelo M; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Koivunen E; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Silvennoinen R; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Räty R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Ruutu T; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Volin L; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Porkka K; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Jantunen E; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Nousiainen T; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Kuittinen T; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Penttilä K; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Pyörälä M; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Säily M; Department of Medicine, Oulu University Hospital, Oulu, Finland., Koistinen P; Department of Medicine, Oulu University Hospital, Oulu, Finland., Kauppila M; Stem Cell Transplantation Unit, Turku University Hospital, Turku, Finland., Itälä-Remes M; Stem Cell Transplantation Unit, Turku University Hospital, Turku, Finland., Ollikainen H; Department of Medicine, Satakunta Central Hospital, Pori, Finland., Rauhala A; The Faculty of Education and Welfare Studies, Department of Health Sciences, Åbo Akademi University, Vaasa, Finland.; Client and Patient Safety Center, Vaasa Central Hospital, Vaasa, Finland., Kairisto V; Laboratory of Molecular Haematology and Pathology, Turku University Central Hospital, Turku, Finland., Pelliniemi TT; Department of Clinical Chemistry, University of Turku, Finland and Fimlab Laboratories Ltd, Tampere, Finland., Elonen E; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.

Publikováno v: European journal of haematology [Eur J Haematol] 2022 Sep; Vol. 109 (3), pp. 257-270. Date of Electronic Publication: 2022 Jun 14.

p53gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma

Autor: Ollikainen H, Koskela K, Kari Pulkki, Syrjänen S, Tarja-Terttu Pelliniemi

Publikováno v: Scandinavian Journal of Clinical and Laboratory Investigation. 57:281-289

We have shown previously that detectable serum concentration of p53 protein is associated with poor prognosis in multiple myeloma (MM). In this study, we studied p53 gene mutations in 29 bone marrow samples of MM patients using polymerase chain react

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e97c7b17498579c1a44d5c6ec54fed
https://doi.org/10.3109/00365519709099401

Liposomal Targeting of Bcl-2 Antisense Oligonucleotides with Enhanced Stability into Human Myeloma Cell Lines

Autor: Stina Syrjänen, Kari Pulkki, Ollikainen H, I Jääskeläinen, Katriina Lappalainen

Publikováno v: Leukemia & Lymphoma. 24:165-174

Cationic liposomes improve the delivery of antisense oligonucleotides (ODNs) into cells. However, there is marked variability in the cellular uptake of ODNs into different cell lines. We used liposomes containing dimethyloctadecylammonium bromide (DD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94a72617f3ae07c5a764a3623e2678c5
https://doi.org/10.3109/10428199609045725

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.

Autor: Luoma S; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. sini.luoma@hus.fi., Anttila P; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Säily M; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland., Lundan T; Department of Clinical Chemistry and TYKSLAB, University of Turku and Turku University Hospital, Turku, Finland., Heiskanen J; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Siitonen T; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland., Kakko S; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland., Putkonen M; Hematology Unit, Turku University Hospital, Turku, Finland., Ollikainen H; Department of Medicine, Satakunta Central Hospital, Pori, Finland., Terävä V; Hematology Unit, Tampere University Hospital, Tampere, Finland., Sankelo M; Hematology Unit, Tampere University Hospital, Tampere, Finland., Partanen A; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.; Department of Medicine, Mikkeli Central Hospital, Mikkeli, Finland., Launonen K; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland.; Department of Medicine, Länsi-Pohja Central Hospital, Kemi, Finland., Räsänen A; Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland., Sikiö A; Department of Medicine, Central Finland Central Hospital, Jyväskylä, Finland., Suominen M; Department of Medicine, Kanta-Häme Central Hospital, Hämeenlinna, Finland., Bazia P; Department of Medicine, Kainuu Central Hospital, Kajaani, Finland., Kananen K; Department of Medicine, Kainuu Central Hospital, Kajaani, Finland., Lievonen J; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Selander T; Science Service Center, Kuopio University Hospital, Kuopio, Finland., Pelliniemi TT; Fimlab Laboratories Ltd., Tampere, Finland., Ilveskero S; HUSLAB Helsinki University Hospital, Helsinki, Finland., Huotari V; Fimlab Laboratories Ltd., Tampere, Finland.; NordLab Oulu, Oulu University Hospital, Oulu, Finland., Mäntymaa P; Laboratory of Eastern Finland, Kuopio University Hospital, Kuopio, Finland., Tienhaara A; Department of Clinical Chemistry and TYKSLAB, University of Turku and Turku University Hospital, Turku, Finland., Jantunen E; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.; Institute of Clinical Medicine/Internal Medicine, University of Eastern Finland, Kuopio, Finland.; Department of Medicine, North Carelia Hospital District, Joensuu, Finland., Silvennoinen R; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.

Publikováno v: Annals of hematology [Ann Hematol] 2019 Dec; Vol. 98 (12), pp. 2781-2792. Date of Electronic Publication: 2019 Oct 31.

Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.

Autor: Remes K; Turku University Hospital and University of Turku, Dept of Clinical Hematology, Turku, Finland., Anttila P; University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland., Silvennoinen R; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Putkonen M; Turku University Hospital and University of Turku, Dept of Clinical Hematology, Turku, Finland., Ollikainen H; Satakunta Central Hospital, Pori, Finland., Terävä V; Päijät-Hämeen Central Hospital, Lahti, Finland., Sinisalo M; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Kananen K; Kainuu Joint Authority for Social and Health Care, Clinic of Internal Medicine, Kajaani, Finland., Schain F; Janssen Cilag AB, Solna, Sweden., Castren-Kortegangas P; Janssen Cilag OY, Espoo, Finland., Järvinen TM; Janssen Cilag OY, Espoo, Finland., Pisini M; Janssen Cilag NV, Beerse, Belgium., Wahl F; Department of Mathematics, Stockholm University, SE, Stockholm, Sweden., Dixon T; JB Medical Ltd, The Old Brickworks, Sudbury, Suffolk, United Kingdom., Leval A; Janssen Cilag AB, Solna, Sweden.; Department of Medical Epidemiology and Biostatistics, Karolinska Instutitet, Stockholm, Sweden.

Publikováno v: PloS one [PLoS One] 2018 Dec 05; Vol. 13 (12), pp. e0208507. Date of Electronic Publication: 2018 Dec 05 (Print Publication: 2018).